Srinivasan Dushyanth, Strohbehn Garth W, Cascino Thomas
Department of Internal Medicine, Yale University, New Haven, CT, 06520-9056, USA.
Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
ESC Heart Fail. 2017 Aug;4(3):384-386. doi: 10.1002/ehf2.12161. Epub 2017 Mar 23.
Angiotensin-converting enzyme inhibitor induced angioedema commonly involves the head and neck area. We report a case of angiotensin-converting enzyme inhibitor induced intestinal angioedema in a heart transplant recipient on mTOR immunosuppression. A 36-year-old Caucasian woman with history of heart transplantation on sirolimus, tacrolimus and prednisone presented to the Emergency Department with abdominal pain, one day following lisinopril initiation. A computer tomography scan demonstrated diffuse bowel wall thickening consistent with pancolitis and edema. She was subsequently diagnosed with angiotensin-converting enzyme inhibitor induced angioedema. Patients on mTOR immunosuppression are at higher risk for this potentially life-threatening side effect. Knowledge of this interaction is critical for providers prescribing mTOR agents.
血管紧张素转换酶抑制剂诱发的血管性水肿通常累及头颈部区域。我们报告一例心脏移植受者在接受mTOR免疫抑制治疗时发生血管紧张素转换酶抑制剂诱发的肠道血管性水肿的病例。一名36岁有心脏移植史、正在服用西罗莫司、他克莫司和泼尼松的白人女性,在开始服用赖诺普利一天后因腹痛就诊于急诊科。计算机断层扫描显示肠壁弥漫性增厚,符合全结肠炎和水肿表现。她随后被诊断为血管紧张素转换酶抑制剂诱发的血管性水肿。接受mTOR免疫抑制治疗的患者发生这种潜在危及生命的副作用的风险更高。了解这种相互作用对于开具mTOR药物的医疗人员至关重要。